A Cost-effectiveness Analysis of Sunitinib vs. Interferon-alpha in Patient with Advanced Renal Cell Carcinoma in Japan
| Autor: | Yumiko Ogawa, Tomiko Sunaga, Masahiro Usuda, Kazuki Tomura, Tadanori Sasaki, Yuki Naito, Hiroyuki Sakamaki, Akiko Nagatani, Nao Akiyama, Mari Kogo, Tatsuya Kurihara, Haruaki Sasaki, Tatsunori Murata |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Pharmacology
Oncology medicine.medical_specialty Sunitinib business.industry Pharmaceutical Science Alpha interferon Cost-effectiveness analysis urologic and male genital diseases medicine.disease Molecular targeting Renal cell carcinoma Internal medicine medicine In patient business Medical expenses Medical costs health care economics and organizations medicine.drug |
| Zdroj: | YAKUGAKU ZASSHI. 138:1397-1407 |
| ISSN: | 1347-5231 0031-6903 |
| DOI: | 10.1248/yakushi.17-00189 |
| Popis: | Sunitinib has been shown to offer clinical benefits during the treatment of advanced renal cell carcinoma. However, molecular targeting drugs are expensive and can have a significant impact on medical expenses. The purpose of this study was to assess the cost-effectiveness of sunitinib as a first-line therapy compared with interferon-alpha (IFN-α) in metastatic renal cell carcinoma patients. A Markov model was used to show the clinical courses of patients with metastatic renal cell carcinoma who received sunitinib or IFN-α. The transition probabilities and utilities employed in this Markov model were derived from two sources. This study focused on the perspective of public healthcare payer, as only direct medical costs were estimated from the treatment schedule for metastatic renal cell cancer. In the cost-effectiveness analysis, outcomes were valued in terms of life years (LYs) and quality-adjusted life years (QALYs). We calculated the incremental cost-effectiveness ratio (ICER) during the cost-effectiveness analysis. The results were tested using Monte Carlo simulations. Sunitinib and IFN-α treatment resulted in LYs of 2.40 years and 2.03 years, QALYs of 1.58 and 1.25, and expected costs of 13,572,629 yen and 6,083,002 yen, respectively. As a result, the ICER associated with replacing IFN-α with sunitinib was 22,695,839 yen/QALYs. Our results suggest that compared with IFN-α, sunitinib prolongs LYs and QALYs, but the increases in quality achieved by sunitinib are more expensive than those produced by IFN-α. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|